leisure time

Why are addiction treatments so hard to get? Can small companies compete in obesity? And since when is “Series E” a thing in biotech?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us to explain his reporting on why virtually every sector of American society is standing in the way of their use. We also discuss the latest news in the life sciences, including the haves and have-nots of venture capital, and the race to develop effective oral treatments for obesity.

advertisement

For more on what we cover, here’s the story on addiction medicine; here’s the latest on biotech financing; here’s more on Novo Nordisk’s oral obesity treatment; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

advertisement